1.Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8).
2.Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626–633.
3.Boehncke WH, Schon MP. Psoriasis. Lancet (London, England). 2015;386(9997):983–994.
4.Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–390.
5.Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
6.Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385–422.
7.Boehncke WH. Etiology and Pathogenesis of Psoriasis. Rheum Dis Clin North Am. 2015;41(4):665–675.
8.Capon F. The Genetic Basis of Psoriasis. Int J Mol Sci. 2017;18(12).
9.Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8.
10.Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004;5(10):1052–1060.
11.Evans PC, Ovaa H, Hamon M, et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J. 2004;378(Pt 3):727–734.
12.Caster DJ, Korte EA, Nanda SK, et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J Am Soc Nephrol. 2013;24(11):1743–1754.
13.Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1062–1064.
14.Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30(8):383–391.
15.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
16.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
17.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
18.Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–748.
19.Bowes J, Orozco G, Flynn E, et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis. 2011;70(9):1641–1644.
20.Haase O, Mosaad H, Eldarouti MA, et al. TNFAIP3 and IL12B gene polymorphisms associated with psoriasis vulgaris in an Egyptian cohort. J Eur Acad Dermatol Venereol. 2015;29(7):1297–1301.
21.Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS. TNFAIP3 and TNIP1 polymorphisms confer psoriasis risk in South Indian Tamils. Br J Biomed Sci. 2015;72(4):168–173.
22.Li XL, Yu H, Wu GS. Investigating the genetic association of HCP5, SPATA2, TNIP1, TNFAIP3 and COG6 with psoriasis in Chinese population. Int J Immunogenet. 2014;41(6):503–507.
23.Yang Q, Liu H, Qu L, et al. Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol. 2013;168(5):1060–1065.
24.Zhang Z, Ma Y, Zhang Z, et al. Identification of Two Loci Associated with Generalized Pustular Psoriasis. J Invest Dermatol. 2015;135(8):2132–2134.
25.Zhang C, Zhu KJ, Liu H, et al. The TNFAIP3 polymorphism rs610604 both associates with the risk of psoriasis vulgaris and affects the clinical severity. Clin Exp Dermatol. 2015;40(4):426–430.
26.Munir S, ber Rahman S, Rehman S, et al. Association analysis of GWAS and candidate gene loci in a Pakistani population with psoriasis. Mol Immunol. 2015;64(1):190–194.
27.Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL–23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199–204.
28.Nikamo P, Lysell J, Stahle M. Association with Genetic Variants in the IL–23 and NF-kappaB Pathways Discriminates between Mild and Severe Psoriasis Skin Disease. J Invest Dermatol. 2015;135(8):1969–1976.
29.Villarreal-Martinez A, Gallardo-Blanco H, Cerda-Flores R, et al. Candidate gene polymorphisms and risk of psoriasis: A pilot study. Exp Ther Med. 2016;11(4):1217–1222.
30.Das S, Stuart PE, Ding J, et al. Fine mapping of eight psoriasis susceptibility loci. Eur J Hum Genet. 2015;23(6):844–853.
31.Han JW, Wang Y, Alateng C, et al. Tumor Necrosis Factor-alpha Induced Protein 3 Interacting Protein 1 Gene Polymorphisms and Pustular Psoriasis in Chinese Han Population. Chin Med J (Engl). 2016;129(13):1519–1524.
32.Ray-Jones H, Eyre S, Barton A, Warren RB. One SNP at a Time: Moving beyond GWAS in Psoriasis. J Invest Dermatol. 2016;136(3):567–573.
33.Linares-Pineda TM, Canadas-Garre M, Sanchez-Pozo A, Calleja-Hernandez MA. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. Pharmacol Res. 2016;113(Pt A):71–80.
34.Dixit VM, Green S, Sarma V, et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem. 1990;265(5):2973–2978.
35.Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430(7000):694–699.
36.Opipari AW, Jr., Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem. 1992;267(18):12424–12427.
37.Jiang X, Tian H, Fan Y, et al. Expression of tumor necrosis factor alpha-induced protein 3 mRNA in peripheral blood mononuclear cells negatively correlates with disease severity in psoriasis vulgaris. Clin Vaccine Immunol. 2012;19(12):1938–1942.
38.Adrianto I, Wen F, Templeton A, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43(3):253–258.
39.Boonyasrisawat W, Eberle D, Bacci S, et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes. 2007;56(2):499–505.
40.Codd JD, Salisbury JR, Packham G, Nicholson LJ. A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma. J Pathol. 1999;187(5):549–555.
41.Hymowitz SG, Wertz IE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer. 2010;10(5):332–341.
42.Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans. 2011;39(4):1086–1091.
43.Shao L, Oshima S, Duong B, et al. A20 restricts wnt signaling in intestinal epithelial cells and suppresses colon carcinogenesis. PLoS One. 2013;8(5):e62223.
44.Saitoh T, Yamamoto M, Miyagishi M, et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol. 2005;174(3):1507–1512.
45.Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014;35(1):22–31.
46.Parvatiyar K, Harhaj EW. Regulation of inflammatory and antiviral signaling by A20. Microbes Infect. 2011;13(3):209–215.
47.Mauro C, Pacifico F, Lavorgna A, et al. ABIN–1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem. 2006;281(27):18482–18488.
48.Kawasaki A, Ito S, Furukawa H, et al. Association of TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese population: a case-control association study. Arthritis Res Ther. 2010;12(5):R174.
49.Allanore Y, Saad M, Dieude P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 2011;7(7):e1002091.
50.Gallagher J, Howlin J, McCarthy C, et al. Identification of Naf1/ABIN–1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett. 2003;551(1–3):8–12.